Author

L. Leypoldt

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma – the BELI(E)VE trial

The BELI(E)VE trial aims to establish a novel personalized therapeutic approach for a specific subset of MM patients by combining belantamab mafodotin and venetoclax, potentially inducing deep and durable remissions in t(11;14)-positive RRMM patients.

C. Schaefers, Cyrus Khandanpour, M. Hänel et al. · BMC Cancer · 0 citations

Review Jul 2026

Precision Oncology in Northern Germany - Integrating Multi-Omics and AI to Support Evidence-Based Molecular Tumor Boards.

This review connects expert perspectives with targeted literature to outline how these emerging methods advance precision oncology and identifies the technical, struc-tural, and clinical requirements for their implementation in clinical use, and highlights how they can improve the quality, speed and accessibility of MT...

J. Vorwerk, L. Leypoldt, Johanna Schwandt et al. · Oncology Research and Treatm... · 0 citations